Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.
Twenty two patients with primary type II hyperlipoproteinemia (13 phenotype IIa and 9 phenotype IIb) were treated with fenofibrate 300 mg a day for 4-12 months. Serum total cholesterol decreased, on the average, by 22 per cent and LDL cholesterol by 24 per cent. In the patients with familial hypercholesterolemia, total cholesterol decreased by 28 per cent and LDL cholesterol by 31 per cent. One patient with homozygous familial hypercholesterolemia showed the greatest fall of total and LDL cholesterol (44 and 48 per cent respectively) and this was accompanied by a nearly complete disappearance of xanthelasmas and xanthomas.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL; D005260:Female; D011345:Fenofibrate / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D011422:Propionates; D014280:Triglycerides; D002784:Cholesterol; C006012:fenofibric acid; D011345:Fenofibrate